Affordable Access

Publisher Website

Male breast cancer

Authors
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
367
Issue
9510
Identifiers
DOI: 10.1016/s0140-6736(06)68226-3
Keywords
  • Review And Opinion
  • Seminar
Disciplines
  • Biology
  • Medicine
  • Physics

Abstract

Summary Occurrence of male breast cancer, a rare disease, peaks at age 71 years. Familial cases usually have BRCA2 rather than BRCA1 mutations. Occupational risks include high temperature environments and exhaust fumes, but electromagnetic fields have not been implicated. Hyperoestrogenisation resulting from Klinefelter's, gonadal dysfunction, obesity, or excess alcohol, all increase risk as does exposure to radiation, whereas gynaecomastia does not. Presentation is usually a lump or nipple inversion, but is often late, with more than 40% of individuals having stage III or IV disease. Most tumours are ductal and 10% are ductal carcinoma in situ. Surgery is usually mastectomy with axillary clearance or sentinel node biopsy. Indications for radiotherapy, by stage, are similar to female breast cancer. Because 90% of tumours are oestrogen-receptor-positive, tamoxifen is standard adjuvant therapy, but some individuals could also benefit from chemotherapy. Hormonal therapy is the main treatment for metastatic disease, but chemotherapy can also provide palliation. National initiatives are increasingly needed to improve information and support for male breast cancer patients.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Male breast cancer.

on Chinese medical journal January 1985

[Male breast cancer].

on Gan to kagaku ryoho. Cancer &... May 2003

Male breast cancer.

on The Lancet Feb 18, 2006

Male breast cancer.

on Oncology 1974
More articles like this..